I looked at this specifically for BAT. SPA might synergize with immunomodulators. As it often happens, I can't get the drugs that are powerful immunomodulators. So I look for natural substances. Usually orders of magnitude weaker but you do what you need to do.
I'm going to try this out during SPA. ATRi is a positive, and senolytic is a negative. So... two pluses and one minus = 1
I'm going to try 6-8g a day. rBAT is only hours or at most a few days so might be good with that. not sure if I'll have gastro issues taking that much for more than a few days.
Once again, I apologize for the weak formatting. FYI: ten clinical trials for curcumin and PCa. 4 are recruiting.
BAT + nivolumab has been trialed. clinicaltrials.gov/ct2/show...
Nivo is an immunomodulator/immune checkpoint inhibitor/PD-L1 inhibitor.
Curcumin as an Immunomodulator in Prostate Cancer: Analysis
Dose, Evidence, Efficacy, and Mechanistic Theory
Aspect Details
Dose 200–8,000 mg/day orally (preclinical: 200–2,000 mg/kg in animal models; clinical: 1,000-8,000 mg/day in phase II trials).
Efficacy (A-F) B: Preclinical synergy with anti-PD-1 agents; limited clinical validation in prostate cancer.
Evidence (A-F) B: Strong preclinical data (STAT3 inhibition, PD-L1 downregulation); moderate human trial data (phase II with docetaxel).
Mechanistic Theory (A-F) A: Inhibits STAT3, reduces PD-L1 expression, converts Tregs to Th1 cells, enhances dendritic cell function.
Mechanisms of Action
1. STAT3 Inhibition: Directly binds to cysteine 259 on STAT3, suppressing IL-6/IL-8 and PD-L1 expression.
2. PD-L1 Downregulation: Reduces PD-L1 on tumor cells, blocking PD-1/PD-L1 interaction and enhancing T-cell cytotoxicity.
3. Immune Modulation: Converts immunosuppressive Tregs to anti-tumor Th1 cells, increases CD8+ T-cell infiltration, and inhibits MDSCs.
Synergy with BAT’s PSA Phase
BAT Phase Curcumin’s Role
High Androgen (PSA Rise) Curcumin reduces IL-6 (linked to STAT3 activation), mitigating androgen-driven inflammation and enhancing T-cell activity against DNA-damaged tumor cells.
Low Androgen Curcumin’s anti-inflammatory effects may reduce resistance to darolutamide/Zytiga by suppressing NF-κB and AR signaling.
Reference List
Rating (A-F) Article Title URL
B Curcumin as an Adjuvant to Cancer Immunotherapy pmc.ncbi.nlm.nih.gov/articl...
A Curcumin interacts directly with the Cysteine 259 residue of STAT3 to inhibit constitutive activation nature.com/articles/s41598-...
B The potential role of curcumin in prostate cancer tcr.amegroups.org/article/v...
B Application and potential value of curcumin in prostate cancer frontiersin.org/journals/ph...
B Combination of curcumin and bicalutamide enhanced growth inhibition in prostate cancer pmc.ncbi.nlm.nih.gov/articl...